Amylin Pharmaceuticals to Present at Research & Development Day
Posted on: Wednesday, 21 November 2007, 09:01 CST
SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at its Research & Development (R&D) Day on Wednesday, November 28, 2007 at 10:00 a.m. ET at the Grand Hyatt Hotel in New York.
"Amylin is focused on bringing innovative medicines with life-changing therapeutic potential to patients through our sustainable approach to the discovery and development of drugs," said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals. "At this year's R&D Day, we look forward to presenting an update on our opportunities to build near-term value with our marketed products, discussing our recent exciting clinical results from the once-weekly exenatide program and the pramlintide/leptin program, and providing insights into our research strategy."
The agenda for this year's R&D Day includes presentations by the following officers of Amylin Pharmaceuticals:
-- Introduction Daniel M. Bradbury President and Chief Executive Officer -- Diabetes Programs Orville Kolterman, MD Senior Vice President of Clinical and Regulatory Affairs -- Obesity Programs Alain Baron, MD Senior Vice President of Research -- Discovery Research Michael Hanley, PhD Vice President of Discovery Research A question and answer session will follow the presentations.
The presentation will be webcast live through Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to http://www.amylin.com/ approximately fifteen minutes prior to the call to register, download and install any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com/.
Amylin Pharmaceuticals, Inc.
CONTACT: Alice Bahner Izzo of Amylin Pharmaceuticals, Inc.,+1-858-642-7272, Cell, +1-858-232-9072, alice.izzo@amylin.com; or RachelMartin of Edelman, +1-323-202-1031, Cell, +1-323-373-5556,rachel.martin@edelman.com, for Amylin Pharmaceuticals, Inc.
Web site: http://www.amylin.com/
Source: PRNewswire-FirstCall
Related Articles
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
- Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
- Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
- Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
- Amylin Pharmaceuticals, Inc. Commits $1.5 Million to American Diabetes Association Distinguished Clinical Scientist Award
- Baylor Researchers Develop 'Bubble' Technique for Diabetes
- Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in Non-Small Cell Lung Cancer
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completes Submission of Tipifarnib NDA to FDA Continuous Marketing Application Pilot-1 Program
 |
 |
User Comments (0)
RSS Feeds